Replies to post #365961 on Amarin Corp Plc (AMRN)

[Gusman]

Thanks NS.

[north40000]

Look in NEJM supplement in late 2018, early 2019. Reduce-It trial active arm patients were on all extant statins at the time of trial. Amarin should be able to rely on data accumulated in that trial. Question is what formulation(s) will be used to support a package approval for Vascepa + statin? Will the statin be in, or outside of, the current Vascepa capsule?